Profund Advisors LLC Cuts Stock Holdings in Insmed, Inc. $INSM

Profund Advisors LLC reduced its position in Insmed, Inc. (NASDAQ:INSM) by 41.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,373 shares of the biopharmaceutical company’s stock after selling 8,185 shares during the period. Profund Advisors LLC’s holdings in Insmed were worth $1,638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Spire Wealth Management increased its holdings in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 80 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in shares of Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 81 shares during the period. Moody Aldrich Partners LLC grew its position in shares of Insmed by 2.4% during the 3rd quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after acquiring an additional 132 shares during the period. AlphaQuest LLC increased its stake in shares of Insmed by 109.5% in the 3rd quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 150 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in Insmed by 169.7% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares during the period.

Insider Buying and Selling at Insmed

In other Insmed news, insider Michael Alexander Smith sold 640 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.27, for a total value of $100,012.80. Following the transaction, the insider directly owned 56,397 shares of the company’s stock, valued at $8,813,159.19. This trade represents a 1.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 3,009 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.34, for a total value of $470,427.06. Following the transaction, the chief executive officer owned 303,882 shares in the company, valued at approximately $47,508,911.88. This represents a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 244,857 shares of company stock valued at $44,301,247 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on INSM shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Wells Fargo & Company set a $195.00 target price on Insmed in a research report on Thursday, December 18th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. HC Wainwright reduced their price objective on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Rothschild & Co Redburn set a $263.00 price objective on shares of Insmed in a report on Thursday, December 4th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $203.45.

Insmed Stock Down 0.7%

Shares of INSM opened at $148.55 on Wednesday. The stock has a 50 day moving average price of $172.50 and a 200 day moving average price of $161.37. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The stock has a market capitalization of $31.68 billion, a price-to-earnings ratio of -24.00 and a beta of 1.11.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.